The role of half-transporters in multidrug resistance

被引:116
作者
Bates, SE
Robey, R
Miyake, K
Rao, K
Ross, DD
Litman, T
机构
[1] NCI, Med Branch, Bethesda, MD 20892 USA
[2] Univ Maryland, Greenebaum Canc Ctr, College Pk, MD 20742 USA
[3] Univ Maryland, Sch Med, Dept Med, Div Hematol Oncol, Baltimore, MD 21201 USA
[4] Vet Adm Med Ctr, Baltimore, MD 21218 USA
[5] Herlev Univ Hosp, Lab Oncol, DK-2730 Herlev, Denmark
关键词
ABCG2; mitoxantrone; ABC transporter; drug resistance gene;
D O I
10.1023/A:1012879205914
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
ATP-binding cassette proteins comprise a superfamily of transporter proteins, a subset of which have been implicated in multidrug resistance. Although P-glycoprotein was described over 15 years ago, the recent expansion in the number of transporters identified has prompted renewed interest in the role of drug transporters in clinical drug resistance. These newly identified transporters include additional members of the MRP family, ABC2, and a new half-transporter, MXR/BCRP/ABCP1. This half-transporter confers high levels of resistance to mitoxantrone, anthracyclines, and the camptothecins SN-38 and topotecan. At 72 kDa, MXR localizes to the plasma membrane in cells which highly overexpress the protein either through gene amplification or though gene rearrangement. Future studies will be aimed at identifying an inhibitor, and attempting to translate recognition of this new transporter into a target for anticancer treatment.
引用
收藏
页码:503 / 511
页数:9
相关论文
共 51 条
  • [41] Novel mechanisms of drug resistance in leukemia
    Ross, DD
    [J]. LEUKEMIA, 2000, 14 (03) : 467 - 473
  • [42] Future perspectives for the development of P-glycoprotein modulators
    Sandor, V
    Fojo, T
    Bates, SE
    [J]. DRUG RESISTANCE UPDATES, 1998, 1 (03) : 190 - 200
  • [43] Scheffer GL, 2000, CANCER RES, V60, P2589
  • [44] A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis
    Strautnieks, SS
    Bull, LN
    Knisely, AS
    Kocoshis, S
    Dahl, N
    Arnell, H
    Sokal, E
    Dahan, K
    Childs, S
    Ling, V
    Tanner, MS
    Kagalwalla, AF
    Németh, A
    Pawlowska, J
    Baker, A
    Mieli-Vergani, G
    Freimer, NB
    Gardiner, RM
    Thompson, RJ
    [J]. NATURE GENETICS, 1998, 20 (03) : 233 - 238
  • [45] DIFFERENT MECHANISMS OF DECREASED DRUG ACCUMULATION IN DOXORUBICIN AND MITOXANTRONE RESISTANT VARIANTS OF THE MCF7 HUMAN BREAST-CANCER CELL-LINE
    TAYLOR, CW
    DALTON, WS
    PARRISH, PR
    GLEASON, MC
    BELLAMY, WT
    THOMPSON, FH
    ROE, DJ
    TRENT, JM
    [J]. BRITISH JOURNAL OF CANCER, 1991, 63 (06) : 923 - 929
  • [46] Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance
    Trock, BJ
    Leonessa, F
    Clarke, R
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (13) : 917 - 931
  • [47] van den Heuvel-Eibrink MM, 2000, INT J CLIN PHARM TH, V38, P94
  • [48] DEVELOPMENT OF RESISTANCE AND CHARACTERISTICS OF A HUMAN-COLON CARCINOMA SUBLINE RESISTANT TO MITOXANTRONE INVITRO
    WALLACE, RE
    LINDH, D
    DURR, FE
    [J]. CANCER INVESTIGATION, 1987, 5 (05) : 417 - 428
  • [49] YANG CHJ, 1995, CANCER RES, V55, P4004
  • [50] ZANG XP, 1994, ONCOL RES, V6, P291